290 related articles for article (PubMed ID: 23947381)
21. Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic fibrosis.
Reeves EP; Williamson M; O'Neill SJ; Greally P; McElvaney NG
Am J Respir Crit Care Med; 2011 Jun; 183(11):1517-23. PubMed ID: 21330456
[TBL] [Abstract][Full Text] [Related]
22. Resistance of the antibacterial agent ceragenin CSA-13 to inactivation by DNA or F-actin and its activity in cystic fibrosis sputum.
Bucki R; Sostarecz AG; Byfield FJ; Savage PB; Janmey PA
J Antimicrob Chemother; 2007 Sep; 60(3):535-45. PubMed ID: 17584802
[TBL] [Abstract][Full Text] [Related]
23. Cystic fibrosis and bacterial colonization define the sputum N-glycosylation phenotype.
Venkatakrishnan V; Thaysen-Andersen M; Chen SC; Nevalainen H; Packer NH
Glycobiology; 2015 Jan; 25(1):88-100. PubMed ID: 25190359
[TBL] [Abstract][Full Text] [Related]
24. Cystic fibrosis sputum induces a secretory response from airway gland serous cells that can be prevented by neutrophil protease inhibitors.
Schuster A; Fahy JV; Ueki I; Nadel JA
Eur Respir J; 1995 Jan; 8(1):10-4. PubMed ID: 7744174
[TBL] [Abstract][Full Text] [Related]
25. High expression of midkine in the airways of patients with cystic fibrosis.
Nordin SL; Jovic S; Kurut A; Andersson C; Gela A; Bjartell A; Mörgelin M; Olin AI; Lund M; Egesten A
Am J Respir Cell Mol Biol; 2013 Dec; 49(6):935-42. PubMed ID: 23815177
[TBL] [Abstract][Full Text] [Related]
26. Protease-antiprotease imbalances differ between Cystic Fibrosis patients' upper and lower airway secretions.
Hentschel J; Fischer N; Janhsen WK; Markert UR; Lehmann T; Sonnemann J; Böer K; Pfister W; Hipler UC; Mainz JG
J Cyst Fibros; 2015 May; 14(3):324-33. PubMed ID: 25286826
[TBL] [Abstract][Full Text] [Related]
27. Cathepsin-G interferes with clearance of Pseudomonas aeruginosa from mouse lungs.
Sedor J; Hogue L; Akers K; Boslaugh S; Schreiber J; Ferkol T
Pediatr Res; 2007 Jan; 61(1):26-31. PubMed ID: 17211136
[TBL] [Abstract][Full Text] [Related]
28. Lactate in cystic fibrosis sputum.
Bensel T; Stotz M; Borneff-Lipp M; Wollschläger B; Wienke A; Taccetti G; Campana S; Meyer KC; Jensen PØ; Lechner U; Ulrich M; Döring G; Worlitzsch D
J Cyst Fibros; 2011 Jan; 10(1):37-44. PubMed ID: 20947455
[TBL] [Abstract][Full Text] [Related]
29. Prolastin aerosol therapy and sputum taurine in cystic fibrosis.
Cantin AM; Berthiaume Y; Cloutier D; Martel M
Clin Invest Med; 2006 Aug; 29(4):201-7. PubMed ID: 16986483
[TBL] [Abstract][Full Text] [Related]
30. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.
Laguna TA; Williams CB; Brandy KR; Welchlin-Bradford C; Moen CE; Reilly CS; Wendt CH
J Cyst Fibros; 2015 May; 14(3):334-40. PubMed ID: 25456770
[TBL] [Abstract][Full Text] [Related]
31. Calprotectin-Mediated Zinc Chelation Inhibits Pseudomonas aeruginosa Protease Activity in Cystic Fibrosis Sputum.
Vermilyea DM; Crocker AW; Gifford AH; Hogan DA
J Bacteriol; 2021 Jun; 203(13):e0010021. PubMed ID: 33927050
[TBL] [Abstract][Full Text] [Related]
32. Proteolytic cleavage of the long pentraxin PTX3 in the airways of cystic fibrosis patients.
Hamon Y; Jaillon S; Person C; Giniès JL; Garo E; Bottazzi B; Ghamrawi S; Urban T; Subra JF; Bouchara JP; Mantovani A; Jeannin P; Delneste Y
Innate Immun; 2013 Dec; 19(6):611-22. PubMed ID: 23475792
[TBL] [Abstract][Full Text] [Related]
33. Lack of neutrophil elastase reduces inflammation, mucus hypersecretion, and emphysema, but not mucus obstruction, in mice with cystic fibrosis-like lung disease.
Gehrig S; Duerr J; Weitnauer M; Wagner CJ; Graeber SY; Schatterny J; Hirtz S; Belaaouaj A; Dalpke AH; Schultz C; Mall MA
Am J Respir Crit Care Med; 2014 May; 189(9):1082-92. PubMed ID: 24678594
[TBL] [Abstract][Full Text] [Related]
34. Neutrophils from F508del cystic fibrosis patients produce IL-17A and express IL-23 - dependent IL-17RC.
Taylor PR; Bonfield TL; Chmiel JF; Pearlman E
Clin Immunol; 2016 Sep; 170():53-60. PubMed ID: 27155366
[TBL] [Abstract][Full Text] [Related]
35. Neutrophilic proteolysis in the cystic fibrosis lung correlates with a pathogenic microbiome.
Quinn RA; Adem S; Mills RH; Comstock W; DeRight Goldasich L; Humphrey G; Aksenov AA; Melnik AV; da Silva R; Ackermann G; Bandeira N; Gonzalez DJ; Conrad D; O'Donoghue AJ; Knight R; Dorrestein PC
Microbiome; 2019 Feb; 7(1):23. PubMed ID: 30760325
[TBL] [Abstract][Full Text] [Related]
36. Antimicrobial peptide therapeutics for cystic fibrosis.
Zhang L; Parente J; Harris SM; Woods DE; Hancock RE; Falla TJ
Antimicrob Agents Chemother; 2005 Jul; 49(7):2921-7. PubMed ID: 15980369
[TBL] [Abstract][Full Text] [Related]
37. Neutrophil cell death, activation and bacterial infection in cystic fibrosis.
Watt AP; Courtney J; Moore J; Ennis M; Elborn JS
Thorax; 2005 Aug; 60(8):659-64. PubMed ID: 16061707
[TBL] [Abstract][Full Text] [Related]
38. Association between pulmonary function and sputum biomarkers in cystic fibrosis.
Mayer-Hamblett N; Aitken ML; Accurso FJ; Kronmal RA; Konstan MW; Burns JL; Sagel SD; Ramsey BW
Am J Respir Crit Care Med; 2007 Apr; 175(8):822-8. PubMed ID: 17234902
[TBL] [Abstract][Full Text] [Related]
39. Aerosol treatment with MNEI suppresses bacterial proliferation in a model of chronic Pseudomonas aeruginosa lung infection.
Woods DE; Cantin A; Cooley J; Kenney DM; Remold-O'Donnell E
Pediatr Pulmonol; 2005 Feb; 39(2):141-9. PubMed ID: 15633200
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
